<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157142</url>
  </required_header>
  <id_info>
    <org_study_id>HLT1301</org_study_id>
    <nct_id>NCT02157142</nct_id>
  </id_info>
  <brief_title>HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON</brief_title>
  <acronym>HORIZON</acronym>
  <official_title>HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HLT Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of the HLT System in&#xD;
      patients with severe aortic stenosis who present at High Risk for aortic valve replacement&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Performance Endpoint 1: Procedural Device Performance</measure>
    <time_frame>Post procedure (day of procedure)</time_frame>
    <description>The primary performance endpoint is the Device Success defined as:&#xD;
Absence of procedural mortality AND&#xD;
Correct positioning of a single HLT Valve into the proper anatomical location AND&#xD;
Intended performance of the HLT Valve (no prosthesis- patient mismatch and mean aortic valve gradient &lt; 20 mmHg or peak aortic valve velocity &lt; 3 m/sec, AND no moderate or severe aortic valve regurgitation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint 2: Mortality at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>The primary safety endpoint is all-cause mortality at 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Endpoint 1: Post-procedural Valve Performance</measure>
    <time_frame>pre-discharge (up to 14 days), 1, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>The HLT Valve performance will be evaluated by the following parameters with echocardiograms obtained at pre-discharge, 1, 6, 12, 24, 36, 48 and 60 months:&#xD;
Aortic valve effective orifice area (EOA)&#xD;
Severity of aortic valve regurgitation (AR)&#xD;
Aortic valve gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoint 2: Adverse Events</measure>
    <time_frame>throughout the 5 year follow up period</time_frame>
    <description>All adverse events will be assessed throughout the 5 year follow up period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Severe Aortic Stenosis</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>HLT Transcatheter Aortic Valve System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HLT Transcatheter Aortic Valve System</intervention_name>
    <description>Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System</description>
    <arm_group_label>HLT Transcatheter Aortic Valve System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 75 years of age or older&#xD;
&#xD;
          2. Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis&#xD;
             with one of the following: aortic valve EOA &lt;1.0 cm2 or 0.6 cm2/m2 , mean aortic valve&#xD;
             gradient &gt;40 mmHg or peak aortic valve velocity &gt;4 m/sec&#xD;
&#xD;
          3. Symptomatology due to aortic stenosis resulting in a New York Heart Association (NYHA)&#xD;
             Functional Classification of II or greater&#xD;
&#xD;
          4. Aortic valve annular diameter ≥ 21 and ≤23mm measured by MSCT&#xD;
&#xD;
          5. An STS score ≥10; or Logistic EuroScore I ≥ 15; or a determination by one&#xD;
             cardiovascular surgeon and one cardiologist that the co-morbidities not captured by&#xD;
             the STS or EuroScore expected to increase the operative mortality risk to &gt; 15%.&#xD;
&#xD;
          6. Geographically available, willing to comply with follow up and able to provide written&#xD;
             informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve&#xD;
             eccentricity (calcific or otherwise) that in the opinion of the investigator could&#xD;
             compromise procedural success.&#xD;
&#xD;
          2. Pre-existing prosthetic heart valve in any position, or prosthetic ring&#xD;
&#xD;
          3. Severe (Grade 3 to 4) aortic, mitral or tricuspid valve regurgitation&#xD;
&#xD;
          4. Moderate to severe mitral stenosis&#xD;
&#xD;
          5. Myocardial infarction within the past 30 days*&#xD;
&#xD;
          6. Echocardiographic evidence of intracardiac mass, thrombus or vegetation&#xD;
&#xD;
          7. LVEF &lt; 30%&#xD;
&#xD;
          8. Uncontrolled hypertension (i.e. blood pressure at baseline &gt; 140 mmHg systolic; or in&#xD;
             the opinion of the investigator cannot be controlled by medical therapy).&#xD;
&#xD;
          9. Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds&#xD;
             of systemic pressure&#xD;
&#xD;
         10. Hemodynamic instability requiring inotropic drug therapy within the past 14 days or&#xD;
             mechanical support within the past 6 months*&#xD;
&#xD;
         11. Untreated clinically significant coronary artery disease requiring revascularization&#xD;
&#xD;
         12. Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which,&#xD;
             in the opinion of the investigator, precludes safe implant delivery&#xD;
&#xD;
         13. Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia,&#xD;
             history of bleeding diathesis or coagulopathy&#xD;
&#xD;
         14. Patient ineligible for or refuses blood transfusions&#xD;
&#xD;
         15. Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive&#xD;
             calcification, severe tortuosity or small vessels) that would preclude passage of&#xD;
             catheters from the femoral arterial access to the aorta as evidenced by peripheral&#xD;
             MSCT&#xD;
&#xD;
         16. Active peptic ulcer or gastrointestinal bleeding within the past 90 days*&#xD;
&#xD;
         17. Stroke or transient ischemic attack within past 6 months*&#xD;
&#xD;
         18. Renal insufficiency as demonstrated by a serum creatinine &gt; 2.5 mg/dL or end stage&#xD;
             renal disease requiring chronic dialysis&#xD;
&#xD;
         19. Active infection requiring ongoing treatment&#xD;
&#xD;
         20. Need for emergent surgery or intervention other than the investigational procedure&#xD;
&#xD;
         21. Any therapeutic invasive cardiac procedure performed or planned to perform within 30&#xD;
             days of the index procedure, (or 6 months for drug eluting coronary stent or&#xD;
             biventricular pacemaker implantation)*&#xD;
&#xD;
         22. Hypersensitivity or contraindication to procedural medication and device materials&#xD;
             (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated&#xD;
&#xD;
         23. Life expectancy &lt; 1 year due to non-cardiac co-morbid conditions&#xD;
&#xD;
         24. Currently participating in any investigational drug or device studies that may&#xD;
             confound the results of this study&#xD;
&#xD;
         25. History of any cognitive or mental health status that would interfere with study&#xD;
             participation&#xD;
&#xD;
        &quot;*&quot;At the time of procedure, if a subject's medical status has changed since enrollment,&#xD;
        the subject shall be re-evaluated for eligibility.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Linke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig - Herzzcntrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Leipzig - Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe aortic stenosis</keyword>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>Transcatheter aortic valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

